Development of novel therapies for pulmonary hypertension by clinical application of basic research

Kimio Satoh, Hiroaki Shimokawa

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pulmonary hypertension is a lethal disease in which inflammation and oxidative stress are deeply involved in the disease state. We have recently screened novel pathogenic molecules and have performed drug discovery targeting those molecules. To confirm its clinical significance, we used patient-derived blood samples to evaluate the potential as a biomarker for diagnosis and prognosis. Finally, we conducted a high-throughput screening and found inhibitors for the pathogenic proteins. In this chapter, we would like to introduce the recent progress on the basic and clinical research focusing on the screening of pathogenic proteins in pulmonary hypertension.

Original languageEnglish
Title of host publicationMolecular Mechanism of Congenital Heart Disease and Pulmonary Hypertension
PublisherSpringer Singapore
Pages125-129
Number of pages5
ISBN (Electronic)9789811511851
ISBN (Print)9789811511844
DOIs
Publication statusPublished - 2020 Jan 1

Keywords

  • Biomarker
  • Diagnosis
  • Drug discovery
  • Pulmonary hypertension
  • Transnational research

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Development of novel therapies for pulmonary hypertension by clinical application of basic research'. Together they form a unique fingerprint.

Cite this